Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glyceraldehyde-3-phosphate dehydrogenase pseudogene 56 (GAPDHP56) is a member of the GAPDH pseudogene family. Pseudogenes are segments of DNA that resemble protein-coding genes but lack the ability to code for a functional protein due to mutations or truncations. GAPDHP56 does not produce an active enzyme and has no established physiological role, therapeutic targeting relevance, or disease association. This distinguishes it from the functional enzyme glyceraldehyde 3-phosphate dehydrogenase (GAPDH), which plays key metabolic and regulatory roles[1][2]. Notes: - Any drug, disease role, or mechanism associated with "GAPDH" does **not** apply to this pseudogene. - "GAPDHP56" is not recommended as a drug discovery or therapeutic target due to its non-coding nature[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glyceraldehyde-3-phosphate dehydrogenase pseudogene 56 (GAPDHP56).